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The main side-effect of transfusion is alloimunization against red blood cells (RBCs)
antigens. Thirteen percent of general population was shown to be responders and 30% of responders make antibodies indicating a rate of alloimmunization of 3.9%. 1 However, alloimmunization is more frequent in Sickle Cell Disease (SCD) patients 2, 3 and is associated with life-threatening complications. [4] [5] [6] This is a major concern in transfusion medicine since transfusion is widely used to treat the complications of SCD and to prevent their occurrence.
To know which SCD-patients are at risk for RBC-immunization and which mismatch are frequently related to antibodies against low-prevalence antigens and (ii) may be important alloantibodies in development. 7 Since the antibody count was weakly dependent on the number of transfusion (Spearman r=0.2856), we assessed the existence of a responder phenotype among SCD patients by applying the procedure developed by Higgins and Sloan. 1 The distribution of the numbers of patients producing different numbers of antibodies was geometric; the frequency of producing an additional antibody was 61.0% and 69% of the SCD patients were responders ( Figure   1 ). This model was strengthened using an independent validation set of SCD patients (n=198) (20.8%) C-positive patients were predicted to express a partial-C phenotype; and 14/400 (3.5%)
could be considered partial-e ( Table 1 ). The occurrence of anti-D was more prevalent in partial-D (17.6%) than in wild-type (3.4%) individuals. Similarly, anti-C was more common in partial than non partial-C individuals. These differences were not statistically significant, but this was probably due to small numbers of patients with the various partial phenotypes. Unexpectedly, anti-e was the most frequent anti-Rh antibodies observed although only 3.5% of patients had a predicted partial-e phenotype. Moreover, anti-e was equally prevalent in partial individual and non-partial individual with or without altered RHCE alleles suggesting that they cannot always be explained by RHCE diversity and therefore these antibodies may be auto-antibodies. In view of the high rate of anti-e (about 10% of all antibodies), and also the rarity of anti-e alone (only one case among 42), it is unclear whether the development of anti-e could be a marker of high-responder status. A prospective study addressing this point would be useful. Overall, among 84 anti-Rh antibodies developed by patients positive for the corresponding antigen, only 10 could be considered to be allo-antibodies, based on the deduced partial phenotype. No correlation between RH alleles or haplotypes and immunization could be established in our study because of the small numbers of individuals with identical genotypes; large multi-center studies are required to provide more rigorous data concerning this issue.
Considering that partial-D, Jk b -negative and S-negative patients are exposed with similar frequencies to the corresponding immunogenic antigens, whereas partial-C and -e patients were exposed twice as frequently as Jk b -negative and S-negative patients (not shown). We compared the risk of a partial-Rh patient producing allo-anti-Rh antibodies when exposed to the complete antigen This study shows that responder SCD patients are at an increased risk of 61% of producing additional antibodies. Interestingly, anti-e was the most prevalent antibody independent of the e variant status of the patients. The partial-D and -C phenotypes seem to be more immunogenic than Jk b and S mismatches but account for only 2% of alloimmunization. This suggest that it may be beneficial to extend matching to the MNS, JK and FY blood groups and the variant profile as soon as the first antibody appears, including antibodies of undetermined specificity. A prospective Partial: either homozygous for an RH allele encoding a partial phenotype or two RH partial alleles in compound heterozygosity; other: patients with either the wild-type allele in trans to the variant allele, or non-partial RH variant, or two RH non-partial variants in compound heterozygosity. In addition, anti-RH6, -RH7 and -RH8 were also observed, for detail see supplementary data (Table S4 ). SUPPLEMENTARY DATA.
MATERIALS AND METHODS

SCD patient cohort and genomic DNA samples
The Genomic DNA was isolated from 400 µl of whole blood collected on ethylene diamine tetra acetate (EDTA) anticoagulant, with a compact nucleic acid isolation system (MagNA Pure compact instrument, Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's instructions.
RHD genotyping by sequencing
For sequence analysis, exon specific polymerase chain reaction (PCR) was performed on genomic DNA as previously described. 1 Initial PCR products and sequencing PCR products 
RHCE genotyping and sequencing
Beadchip RhCE kit (BioArray Solutions, Immucor France) was used for DNA array analysis in accordance with the manufacturer's instructions. The RhCE kit investigates 28 polymorphisms associated with RhCE variants. All samples presenting one RHCE*Ce allele were investigated for the presence of the RHCE*CeRN variant. Allelic discrimination was performed using TaqMan® probes as previously described. 2 PCR amplification and sequencing of RHCE exons were as previously described 4 .
Briefly, amplifications were performed on 100 ng of genomic DNA in a final volume of 50 µl The annealing temperature was decreased from 66°C to 60°C in increments of 1°C every two cycles, with a total of 30 cycles with annealing at 60°C. PCR products were assessed by electrophoresis on 1.5% (w/v) agarose gel, and the amplification products were sequenced by GATC Biotec (Konstanz, Germany).
Extended phenotyping of transfused red blood cell units
Data describing the extended phenotype of transfused RBC units were not available retrospectively in the patient files of our cohort. Therefore, to estimate the routine exposure to the positive antigen of SCD patients who were Jk b negative, S-negative or in the partial Rh blood group, 930 RBCs units destined to SCD patients were phenotyped for Kidd and MNS blood groups.
Statistical analysis
Correlation between RBC unit count and immunization was evaluated using the Spearman correlation test (http://marne.u707.jussieu.fr/biostatgv/). Immunization frequencies were compared with Fisher's exact test (http://aoki2.si.gunma-u.ac.jp/exact/exact.html). In every test, differences with a p value ≤0.05 were considered to be statistically significant and power of statistical analysis was ≥ to 80%.
RESULTS
RHD allele frequency and deduced partial D phenotypes in patients
D+ SCD patients were investigated for RHD allele variants by stepwise sequencing of RHD exons. The frequencies of the various RHD alleles are reported in Table S1 and compared to published data. patients were D+C-E-c+e+. In addition, ten samples were found to display novel RHD alleles (Table S2) .
RHCE allele's frequency
We screened D+ SCD patients for RHCE allele variants using Beadchip RhCE kits.
All samples with a RHCE*Ce allele were also tested for RHCe*RN and the RHCE exon 2 was sequenced to test for the RHCE*ce(254) allele. Note that neither of these partial variants are detected by the Beadchip RhCE kit. New polymorphisms were detected in 20 samples (Table   S1 ). The frequencies of other RHCE variants were calculated, and comparisons with published data revealed no noteworthy differences (Table S1) (Table S3) .
Antibodies against the antigens of the Rh system
Antibodies (n= 154) against the Rh antigens were identified in 93 SCD patients. The most frequent antibodies were directed against D, C and e. Eighty-four of the 154 antibodies (54.5%) were found in patients with a positive phenotype for the corresponding antigen.
These antibodies were rarely found as single antibody (Table S4) . 
